Drugs used to treat opioid use disorder may also be successful in improving the health outcomes of patients admitted to the hospital for injection drug use-associated endocarditis, according to research out of Boston.
A wearable sensor developed by researchers at University of Utah Health and VA Salt Lake City Health Care System has the potential to predict heart failure complications more than a week before they occur.
A 92.6% reduction in the list price of tafamidis—an effective but ultimately unaffordable drug designed to treat transthyretin amyloid cardiomyopathy—would be required to make the medication accessible to the average heart patient, researchers reported in Circulation Feb. 12.
Medtronic and the FDA were both aware of battery and wire connection defects in a now-recalled heart failure pacemaker for over a year before patients developed serious side effects, according to a report published in JAMA Internal Medicine.
Despite other quality of life improvements, heart patients supported by left ventricular assist devices face “severely impaired” exercise capacity, according to a study published online in JACC: Heart Failure.